Protox files foundation patent for PORxin(TM) technology
Advertisement
Protox Therapeutics Inc. announced that it has filed a provisional patent application with the United States Patent and Trademark Office entitled "Modified Pore-Forming Toxins and Use Thereof". This is a foundational patent application, intended to encompass and protect several aspects of the Company's entire PORxin(TM) technology. Under this application the Company's ability to develop individual protoxin candidates to act as either "broad spectrum" anti-cancer agents or to treat specific cancer types would be protected.
The Company's ability to modify pore-forming toxins so that general or specific cleavage agents can activate them is included in the application's claims, together with other modifications that allow selective targeting of pore forming toxins to specific cells. The Company anticipates that one or more of these modified pore forming toxins may be useful in the treatment of specific forms of cancer and other diseases.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Restless_legs_syndrome
Fresenius Kabi and Octapharma Group enter into an Exclusive Agreement for a HESylated recombinant protein
Pepscan Therapeutics closes a Research and License Agreement aimed at the development of novel vaccines
United_States_Environmental_Protection_Agency
Antimicrobial_pharmacodynamics
Nymox Announces New Positive Results from 3 1/2 Year Study of NX-1207 for Benign Prostatic Hyperplasia
Laparoscopic_surgery
Category:Glands
ExonHit Announces Termination of Agreement to Acquire RedPath
